Related Experiment Video
Updated: Jul 19, 2026
12:21
Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
Published on: November 27, 2016
Pooling pharmacogenetic studies on the serotonin transporter: a mega-analysis
Alessandro Serretti1, Cristina Cusin, Jeffrey L Rausch
1Department of Psychiatry, Vita-Salute University, Fondazione Centro San Raffaele del Monte Tabor, Milan, Italy. serretti.alessandro@hsr.it
Psychiatry Research
|October 31, 2006
Summary
Individuals with the SERPR l/l genotype showed better response to selective serotonin reuptake inhibitors (SSRIs) antidepressants. This finding supports the serotonin transporter gene
Area of Science:
- Pharmacogenetics
- Neuroscience
- Genetics
Background:
- Pharmacogenetic studies suggest a link between the serotonin transporter gene (SERTPR) promoter and antidepressant response.
- Individual differences in treatment efficacy for depression are a significant clinical challenge.
Purpose of the Study:
- To investigate the role of the serotonin transporter gene (SERTPR) in the efficacy of selective serotonin reuptake inhibitors (SSRIs).
- To pool data from multiple studies for a robust analysis of SERTPR variants and antidepressant response.
Main Methods:
- A meta-analysis of three pharmacogenetic studies involving 548 patients treated with SSRIs.
- Assessment of depressive symptom severity using the Hamilton Rating Scale for Depression.
- Determination of SERTPR allelic variants via PCR-based techniques.
Main Results:
- Patients with the SERPR l/l genotype demonstrated a significantly better response to SSRI treatment across the pooled sample.
- This association remained significant and independent of demographic and clinical variables.
- The effect, however, was not uniform across all individual study samples.
Conclusions:
- The serotonin transporter gene (SERTPR) plays a role in predicting response to antidepressant treatment with SSRIs.
- The SERPR l/l genotype may serve as a potential biomarker for treatment efficacy in depression.
Related Concept Videos
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...